Mitko Mladenov

Prof. Dr. Mitko Mladenov

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 May 2023 in Antioxidants
Verified
Journal Article
Open access
PDF file
MMMitko Mladenov
Mitko Mladenov
LLLubomir Lubomirov
Lubomir Lubomirov
OGOlaf Grisk
Olaf Grisk
Dimiter AvtanskiDimiter Avtanski
Dimiter Avtanski
VMVadim Mitrokhin
Vadim Mitrokhin
HGHristo Gagov
Hristo Gagov
This review is focused on the mechanisms that regulate health, disease and aging redox status, the signal pathways that counteract oxidative and reductive stress, the role of food components and additives with antioxidant properties (curcumin, polyphenols, vitamins, carotenoids, flavonoids, etc.), and the role of the hormones irisin and melatonin in the redox homeostasis of animal and human cells. The correlations between the deviation from optimal redox conditions and inflammation, allergic, aging and autoimmune responses are discussed. Special attention is given to the vascular system, kidney, liver and brain oxidative stress processes. The role of hydrogen peroxide as an intracellular and paracrine signal molecule is also reviewed. The cyanotoxins β-N-methylamino-l-alanine (BMAA), cylindrospermopsin, microcystins and nodularins are introduced as potentially dangerous food and environment pro-oxidants.

24 March 2025 in Cancers
Verified
Journal Article
Open access
PDF file
SSSajal Raj Singh
Sajal Raj Singh
RBRakesh Bhaskar
Rakesh Bhaskar
SGShampa Ghosh
Shampa Ghosh
BYBhuvaneshwar Yarlagadda
Bhuvaneshwar Yarlagadda
Krishna Kumar SinghKrishna Kumar Singh
Krishna Kumar Singh
Dimiter AvtanskiDimiter Avtanski
Dimiter Avtanski
Cancer is complex because of the critical imbalance in genetic regulation as characterized by both the overexpression of oncogenes (OGs), mainly through mutations, amplifications, and translocations, and the inactivation of tumor-suppressor genes (TSGs), which entail the preservation of genomic integrity by inducing apoptosis to counter the malignant growth. Reviewing the intricate molecular interplay between OGs and TSGs draws attention to their cell cycle, apoptosis, and cancer metabolism regulation. In the present review, we discuss seminal discoveries, such as Knudson’s two-hit hypothesis, which framed the field’s understanding of cancer genetics, leading to the next breakthroughs with next-generation sequencing and epigenetic profiling, revealing novel insights into OG and TSG dysregulation with opportunities for targeted therapy. The key pathways, such as MAPK/ERK, PI3K/AKT/mTOR, and Wnt/β-catenin, are presented in the context of tumor progression. Importantly, we further highlighted the advances in therapeutic strategies, including inhibitors of KRAS and MYC and restoration of TSG function, despite which mechanisms of resistance and tumor heterogeneity pose daunting challenges. A high-level understanding of interactions between OG-TSGs forms the basis for effective, personalized cancer treatment—something to strive for in better clinical outcomes. This synthesis should integrate foundational biology with translation and, in this case, contribute to the ongoing effort against cancer.

13 December 2015 in Physiological Research
Verified
Journal Article
Closed access
MMMitko Mladenov
Mitko Mladenov
MGM. Gokik
M. Gokik
NHN. Hadzi-Petrushev
N. Hadzi-Petrushev
IGI. Gjorgoski
I. Gjorgoski
NJN. Jankulovski
N. Jankulovski
The aim of this study was to gain more complete information about the relationships between some endogenous antioxidants and the malondialdehyde (MDA) as a marker of lipid peroxidation, during D-galactose induced senescence. The activities of superoxide dismutase (SOD), glutathione peroxidase (GPx), catalase (CAT) and the concentrations of uric acid (UA) in plasma and MDA in erythrocyte’s hemolysate, were determined in 15 D-galactose (D-gal), treated rats and compared with 15 placebo. The activity of the erythrocyte’s CAT was found significantly increased due to the senescence. The ratio of the activities of antioxidant enzymes R=SOD/(GPx+CAT) was significantly decreased due to the senescence and negatively correlated with the MDA (ρ=–0.524, p=0.045). The antioxidant enzymes SOD and GPx negatively correlated with the MDA, while CAT displayed no correlation. Further, the UA positively correlated with the ratio of activities of the antioxidant enzymes R=SOD/(GPx+CAT), (ρ=0.564, p=0.029 for senescent rats). Obtained results may contribute to better understanding of the process of D-gal induced senescence in the erythrocytes.

17 March 2025 in Cancers
Verified
Journal Article
Open access
PDF file
Radoslav StojchevskiRadoslav Stojchevski
Radoslav Stojchevski
ESEdward Agus Sutanto
Edward Agus Sutanto
RSRinni Sutanto
Rinni Sutanto
NHNikola Hadzi-Petrushev
Nikola Hadzi-Petrushev
MMMitko Mladenov
Mitko Mladenov
Dimiter AvtanskiDimiter Avtanski
Dimiter Avtanski
Cancer, characterized by the uncontrolled proliferation of cells, is one of the leading causes of death globally, with approximately one in five people developing the disease in their lifetime. While many driver genes were identified decades ago, and most cancers can be classified based on morphology and progression, there is still a significant gap in knowledge about genetic aberrations and nuclear DNA damage. The study of two critical groups of genes—tumor suppressors, which inhibit proliferation and promote apoptosis, and oncogenes, which regulate proliferation and survival—can help to understand the genomic causes behind tumorigenesis, leading to more personalized approaches to diagnosis and treatment. Aberration of tumor suppressors, which undergo two-hit and loss-of-function mutations, and oncogenes, activated forms of proto-oncogenes that experience one-hit and gain-of-function mutations, are responsible for the dysregulation of key signaling pathways that regulate cell division, such as p53, Rb, Ras/Raf/ERK/MAPK, PI3K/AKT, and Wnt/β-catenin. Modern breakthroughs in genomics research, like next-generation sequencing, have provided efficient strategies for mapping unique genomic changes that contribute to tumor heterogeneity. Novel therapeutic approaches have enabled personalized medicine, helping address genetic variability in tumor suppressors and oncogenes. This comprehensive review examines the molecular mechanisms behind tumor-suppressor genes and oncogenes, the key signaling pathways they regulate, epigenetic modifications, tumor heterogeneity, and the drug resistance mechanisms that drive carcinogenesis. Moreover, the review explores the clinical application of sequencing techniques, multiomics, diagnostic procedures, pharmacogenomics, and personalized treatment and prevention options, discussing future directions for emerging technologies.

1 March 2018 in Life Sciences
Verified
Journal Article
Closed access
NHNikola Hadzi-Petrushev
Nikola Hadzi-Petrushev
JBJane Bogdanov
Jane Bogdanov
JKJovanka Krajoska
Jovanka Krajoska
JIJovana Ilievska
Jovana Ilievska
BBBiljana Bogdanova-Popov
Biljana Bogdanova-Popov
MMMitko Mladenov
Mitko Mladenov

20 November 2023 in Cancers
Verified
Journal Article
Open access
PDF file
ISIliyana Sazdova
Iliyana Sazdova
Milena Keremidarska-MarkovaMilena Keremidarska-Markova
Milena Keremidarska-Markova
DDDaniela Zdravkova Dimitrova
Daniela Zdravkova Dimitrova
VMVadim Mitrokhin
Vadim Mitrokhin
AKAndre Kamkin
Andre Kamkin
MMMitko Mladenov
Mitko Mladenov
EF24, a synthetic monocarbonyl analog of curcumin, shows significant potential as an anticancer agent with both chemopreventive and chemotherapeutic properties. It exhibits rapid absorption, extensive tissue distribution, and efficient metabolism, ensuring optimal bioavailability and sustained exposure of the target tissues. The ability of EF24 to penetrate biological barriers and accumulate at tumor sites makes it advantageous for effective cancer treatment. Studies have demonstrated EF24’s remarkable efficacy against various cancers, including breast, lung, prostate, colon, and pancreatic cancer. The unique mechanism of action of EF24 involves modulation of the nuclear factor-kappa B (NF-κB) and nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathways, disrupting cancer-promoting inflammation and oxidative stress. EF24 inhibits tumor growth by inducing cell cycle arrest and apoptosis, mainly through inhibiting the NF-κB pathway and by regulating key genes by modulating microRNA (miRNA) expression or the proteasomal pathway. In summary, EF24 is a promising anticancer compound with a unique mechanism of action that makes it effective against various cancers. Its ability to enhance the effects of conventional therapies, coupled with improvements in drug delivery systems, could make it a valuable asset in cancer treatment. However, addressing its solubility and stability challenges will be crucial for its successful clinical application.